Reduced Insulinotropic Effects of Glucagonlike Peptide I-(7–36)-Amide and Gastric Inhibitory Polypeptide in Isolated Perfused Diabetic Rat Pancreas
The DOI matches its Crossref record.
Abstract
The pathophysiological role of incretin in diabetes mellitus has not been established. We therefore examined the effects of glucagonlike peptide l-(7–36)-amide (truncated GLP-I) and gastric inhibitory polypeptide (GIP) on insulin and glucagon release from isolated perfused pancreases of diabetic rats (12–14 wk of age, mean ± SE fasting plasma glucose 8.9 ± 0.6 mM, n = 25) after an injection of 90 mg/kg streptozocin on the 2nd day after birth and compared the results with those of nondiabetic control rats. In diabetic rats, the infusion of 1 nM GLP-I or GIP in perfusates with varying glucose concentrations (2.8, 5.6, 8.3,11.1, or 22.2 mM) caused a nearly equal degree of insulin stimulation from a similar basal insulin level. Meanwhile, basal and GLP-I- or GIPstimulated insulin release increased in correlation with the ambient glucose concentration in nondiabetic rats. The degree of stimulation of insulin release at glucose concentrations of 5.6 mM in diabetic rats was −33% that of nondiabetic rats. The stimulation potency was the same between GLP-I and GIP. The insulin treatment for diabetic rats (5 U/kg NPH insulin at 0900 and 2100 for 6 days) brought only a slight improvement in the glucose dependency of GLP-I-stimulated insulin release. The effects of GLP-I and GIP on glucagon release were completely opposite. GLP-I suppressed release; GIP stimulated it. In diabetic rats, the degree of suppression by GLP-I and stimulation by GIP were almost the same with similar basal glucagon levels in the perfusate with varying glucose concentrations. In nondiabetic rats, these parameters were inversely correlated with ambient glucose concentrations. Insulin treatment did not improve the glucose dependency of either the basal glucagon level or the degree of suppression by GLP-I. These data demonstrate that the incretin effect of GLP-I and GIP, glucose-dependent stimulation of insulin release, is reduced in neonatal streptozocin-induced diabetic rats and that conventional insulin treatment does not normalize this abnormality. Also, inhibition of glucagon release by GLP-I is glucose dependent in nondiabetic rats, and this glucose dependency is lost in diabetic rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Unimolecular oligo-hormonal agonists address more than just GLP-1 receptors One avenue of further increasing the potency of GLP-1 RAs is developing molecules that address not only GLP-1 receptors, but a second (co-agonist) or even a third (tri-agonist) receptor (choosing from glucagon, glucose-dependent insulinotropic…”
BackgroundKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Metadata
- Authors
- Suzuki, S., Kawai, K., Ohashi, S., Mukai, H., Murayama, Y., & Yamashita, K.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1990-11-01
- Volume
- 39
- Issue
- 11
- Pages
- 1320-1325
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2167924331
- Cited by
- 41
- References
- 0
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Insulinotropic Effects of Glucagonlike Peptide I-(7–36)-Amide and Gastric Inhibitory Polypeptide in Isolated Perfused Diabetic Rat Pancreas. https://app.cochat.ai/papers/10.2337/diab.39.11.1320
- The paper
- Suzuki, S., Kawai, K., Ohashi, S., Mukai, H., Murayama, Y., & Yamashita, K. (1990). Reduced Insulinotropic Effects of Glucagonlike Peptide I-(7–36)-Amide and Gastric Inhibitory Polypeptide in Isolated Perfused Diabetic Rat Pancreas. Diabetes. https://doi.org/10.2337/diab.39.11.1320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.